FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025811041> ?p ?o ?g. }

• W2025811041 endingPage "364" @default.
• W2025811041 startingPage "356" @default.
• W2025811041 abstract "Among several commonly used atypical antipsychotic drugs, olanzapine and risperidone cause a sensitization effect in the conditioned avoidance response (CAR) and phencyclidine (PCP)-induced hyperlocomotion paradigms – two well established animal tests of antipsychotic drugs, whereas clozapine causes a tolerance effect. Asenapine is a novel antipsychotic drug recently approved for the treatment of schizophrenia and manic disorders. It shares several receptor binding sites and behavioral features with other atypical antipsychotic drugs. However, it is not clear what type of repeated effect (sensitization or tolerance) asenapine would induce, and whether such an effect is transferrable to other atypicals. In this study, male adult Sprague-Dawley rats were first repeatedly tested with asenapine (0.05, 0.10 or 0.20 mg/kg, sc) for avoidance response or PCP (3.20 mg/kg, sc)-induced hyperlocomotion daily for 5 consecutive days. After 2–3 days of retraining/drug-free recovery, they were then challenged with asenapine (0.10 mg/kg, sc), followed by olanzapine (0.50 mg/kg, sc) and clozapine (2.50 mg/kg, sc). During the 5-day drug test period (the induction phase), repeated asenapine treatment progressively increased its inhibition of avoidance response and PCP-induced hyperlocomotion in a dose-dependent fashion. On the asenapine and olanzapine challenge tests (the expression phase), rats previously treated with asenapine still showed significantly lower avoidance response and lower PCP-induced hyperlocomotion than those previously treated with vehicle. An increased reactivity to clozapine challenge in prior asenapine-treated rats was also found in the PCP-induced hyperlocomotion test. These findings suggest that asenapine is capable of inducing a sensitization effect and a cross-sensitization to olanzapine and clozapine (to a lesser extent). Because the behavioral profile of asenapine in both tests is similar to that of olanzapine, but different from that of clozapine, we suggest that asenapine resembles olanzapine to a greater extent than clozapine in its therapeutic and side effect profiles." @default.
• W2025811041 created "2016-06-24" @default.
• W2025811041 creator A5029805109 @default.
• W2025811041 creator A5039903670 @default.
• W2025811041 creator A5066725248 @default.
• W2025811041 date "2013-12-01" @default.
• W2025811041 modified "2023-09-24" @default.
• W2025811041 title "Repeated asenapine treatment produces a sensitization effect in two preclinical tests of antipsychotic activity" @default.
• W2025811041 cites W1720397775 @default.
• W2025811041 cites W1966009386 @default.
• W2025811041 cites W1969828453 @default.
• W2025811041 cites W1971913921 @default.
• W2025811041 cites W1985245833 @default.
• W2025811041 cites W1989004497 @default.
• W2025811041 cites W1998405751 @default.
• W2025811041 cites W2005295271 @default.
• W2025811041 cites W2015572911 @default.
• W2025811041 cites W2018742347 @default.
• W2025811041 cites W2024267348 @default.
• W2025811041 cites W2026528445 @default.
• W2025811041 cites W2028441561 @default.
• W2025811041 cites W2030445167 @default.
• W2025811041 cites W2034967655 @default.
• W2025811041 cites W2045404197 @default.
• W2025811041 cites W2055126281 @default.
• W2025811041 cites W2058660556 @default.
• W2025811041 cites W2059441616 @default.
• W2025811041 cites W2062363772 @default.
• W2025811041 cites W2065032992 @default.
• W2025811041 cites W2067908875 @default.
• W2025811041 cites W2069287861 @default.
• W2025811041 cites W2070671526 @default.
• W2025811041 cites W2074140506 @default.
• W2025811041 cites W2075174032 @default.
• W2025811041 cites W2078467132 @default.
• W2025811041 cites W2081000541 @default.
• W2025811041 cites W2081845512 @default.
• W2025811041 cites W2084253035 @default.
• W2025811041 cites W2087350312 @default.
• W2025811041 cites W2088626092 @default.
• W2025811041 cites W2089931568 @default.
• W2025811041 cites W2093286170 @default.
• W2025811041 cites W2098875962 @default.
• W2025811041 cites W2101771761 @default.
• W2025811041 cites W2103643413 @default.
• W2025811041 cites W2135162974 @default.
• W2025811041 cites W2147015928 @default.
• W2025811041 cites W2150410734 @default.
• W2025811041 cites W2159992706 @default.
• W2025811041 cites W2316454641 @default.
• W2025811041 cites W2327848520 @default.
• W2025811041 cites W4237352278 @default.
• W2025811041 doi "https://doi.org/10.1016/j.neuropharm.2013.05.031" @default.
• W2025811041 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3865020" @default.
• W2025811041 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23954676" @default.
• W2025811041 hasPublicationYear "2013" @default.
• W2025811041 type Work @default.
• W2025811041 sameAs 2025811041 @default.
• W2025811041 citedByCount "17" @default.
• W2025811041 countsByYear W20258110412013 @default.
• W2025811041 countsByYear W20258110412014 @default.
• W2025811041 countsByYear W20258110412015 @default.
• W2025811041 countsByYear W20258110412016 @default.
• W2025811041 countsByYear W20258110412017 @default.
• W2025811041 countsByYear W20258110412018 @default.
• W2025811041 countsByYear W20258110412021 @default.
• W2025811041 crossrefType "journal-article" @default.
• W2025811041 hasAuthorship W2025811041A5029805109 @default.
• W2025811041 hasAuthorship W2025811041A5039903670 @default.
• W2025811041 hasAuthorship W2025811041A5066725248 @default.
• W2025811041 hasBestOaLocation W20258110412 @default.
• W2025811041 hasConcept C118552586 @default.
• W2025811041 hasConcept C126322002 @default.
• W2025811041 hasConcept C170493617 @default.
• W2025811041 hasConcept C203014093 @default.
• W2025811041 hasConcept C2776217527 @default.
• W2025811041 hasConcept C2776412080 @default.
• W2025811041 hasConcept C2776619155 @default.
• W2025811041 hasConcept C2776921671 @default.
• W2025811041 hasConcept C2778851735 @default.
• W2025811041 hasConcept C2779626651 @default.
• W2025811041 hasConcept C2780057945 @default.
• W2025811041 hasConcept C2780494398 @default.
• W2025811041 hasConcept C2780864610 @default.
• W2025811041 hasConcept C67018056 @default.
• W2025811041 hasConcept C71924100 @default.
• W2025811041 hasConcept C98274493 @default.
• W2025811041 hasConceptScore W2025811041C118552586 @default.
• W2025811041 hasConceptScore W2025811041C126322002 @default.
• W2025811041 hasConceptScore W2025811041C170493617 @default.
• W2025811041 hasConceptScore W2025811041C203014093 @default.
• W2025811041 hasConceptScore W2025811041C2776217527 @default.
• W2025811041 hasConceptScore W2025811041C2776412080 @default.
• W2025811041 hasConceptScore W2025811041C2776619155 @default.
• W2025811041 hasConceptScore W2025811041C2776921671 @default.
• W2025811041 hasConceptScore W2025811041C2778851735 @default.
• W2025811041 hasConceptScore W2025811041C2779626651 @default.
• W2025811041 hasConceptScore W2025811041C2780057945 @default.

• next